Abstract Purpose: Prostate-specific membrane antigen (PSMA) is a cell surface protein that is overexpressed in prostate cancer, including hormone-refractory and metastatic disease. Our goal in this study was to develop a series of PSMA-based imaging agents for clinical use. Experimental Design: We have synthesized and evaluated the in vivo biodistribution of two radiolabeled urea derivatives that have high affinity for PSMA in severe combined immunodeficient mice harboring MCF-7 (breast, PSMA-negative), PC-3 (prostate, PSMA-negative), and LNCaP (prostate, PSMA-positive) xenografts. Radiopharmaceutical binding selectivity and tumor uptake were also evaluated in vivo using dedicated small animal positron emission tomography, single photon emission computed tomography, and gamma scintigraphic imaging devices.
I]DCIT showed tumor/muscle ratios of 10.8 and 4.7, respectively, with clear delineation of LNCaP-derived tumors on imaging. MCF-7-and PC-3-derived tumors showed significantly less uptake of [ Prostate cancer will be diagnosed and treated in 230,000 men in the United States in 2004 (1) . Prostate cancer is currently diagnosed by sector biopsy in men presenting with an elevated serum prostate-specific antigen level. As for all biopsies, sector biopsy for prostate cancer is invasive and limited by sampling error. More accurate staging would facilitate treatment decisions and lead to a better outcome for patients. Badly needed is a method by which to detect small lesions (i.e., recurrent tumors in the surgical bed) and other subtle manifestations of the disease in men with an elevated serum prostate-specific antigen but no other symptoms. Diagnostic imaging could provide a full picture of prostate tumor burden by uncovering recurrent and metastatic lesions. Particularly useful would be an imaging technique that could be correlated with a relevant tumor phenotype (e.g., serve as a biomarker for androgenindependent disease).
Prostate-specific membrane antigen (PSMA) provides an excellent target for prostate tumor imaging and therapy because of its transmembrane location and the fact that it is significantly up-regulated in prostate cancer and metastasis relative to the few normal tissues in which it resides (2) . PSMA is also strongly expressed in the neovasculature of many solid tumors but oddly enough not in that of prostate cancer (3 -5) . 111 InCapromab pendetide (ProstaScint) is a commercially available monoclonal antibody in clinical use for detecting prostate cancer but has been cited for complexities associated with its administration and the interpretation of the images obtained (6 -8) . Furthermore, antibody-mediated imaging is known to suffer from inherently difficult pharmacokinetics, including limited access to tumors and slow washout rates that produce significant background radioactivity (i.e., low signal-to-noise ratio; refs. 9, 10). We have synthesized two small-molecule ligands for PSMA, one in positron-emitting form ( 11 C) for positron emission tomography (PET) and the other labeled with 125 I for single photon emission computed tomography (SPECT) and gamma scintigraphy in rodents, and use them to perform imaging of PSMA-positive and PSMA-negative lesions in experimental models of prostate cancer in vivo.
Materials and Methods
Cell lines and mouse models. MCF-7, PC-3, and LNCaP cell lines were obtained from the American Type Culture Collection (Rockville, MD), maintained in EMEM (Mediatech, Inc., Herndon, VA; MCF-7) and RPMI 1640 (PC-3 and LNCaP), and supplemented as described previously (11) . All cells were grown to 80% to 90% confluence before trypsinization and formulation into an equal volume of HBSS (Sigma, St. Louis, MO) and Matrigel (Becton Dickinson, San Jose, CA) for implantation into mice.
All animal studies were carried out in full compliance with institutional guidelines related to the conduct of animal experiments. Male (for PC-3 and LNCaP) or female (for MCF-7) severe combined immunodeficient (SCID) mice (Charles River Laboratories, Wilmington, MA) were implanted s.c. with 1 Â 10 6 to 5 Â 10 6 cells in Matrigel forward of the left flank. SCID mice were derived on a CD17 background. Mice were imaged or used in biodistribution assays when the tumor xenografts reached 5 to 7 mm in diameter. Glutamate carboxypeptidase II (GCPII) knockout mice were provided by Dr. Warren D. Heston and generated as described previously (12) .
Chemistry and radiochemistry. All chemicals and solvents were of American Chemical Society or high-performance liquid chromatography (HPLC) purity and were used as received. (14) .
carbamoyl]-L-tyrosine) was synthesized as described previously (15) . Radio-iodination of DCIT followed the Iodogen method (16) . Briefly, DCIT precursor (100 Ag) was dissolved in 100 AL phosphate-buffered NaCl solution (pH 7.5). This solution was added to a 4 mL glass vial containing 100 Ag coated Iodogen. [
125 I]NaI (1-5 mCi; MP Biomedicals, Costa Mesa, CA) was then added to the vial and the reaction proceeded at ambient temperature for 15 minutes. The solution was then withdrawn and purified by preparative HPLC. A Phenomenex (Torrance, CA) C 18 Luna 250 Â 10 mm column was used with 20% MeCN in 0.1% trifluoroacetic acid flowing at 6 mL/min. Product elution was monitored by a radioactivity detector and UV absorbance was monitored concurrently at 254 nm. The product was collected and concentrated under vacuum. [
125 I]DCIT identity and purity were verified by analytic HPLC coinjection with unradiolabeled standard provided by Dr. Alan P. Kozikowski. Analytic HPLC conditions included the use of a 5.6 Â 150 mm Phenomenex C 18 Luna column flowing at 2 mL/min using 20% MeCN in 0.1% trifluoroacetic acid. The final product was formulated in sterile, physiologic NaCl solution at 1 mCi/mL and was filtered through a 0.22 Am syringe filter before storage in a sterile dose vial. The radiotracer was stored at 4jC until use.
In vitro binding assays. Taking advantage of the N-acetylaspartylglutamate (NAAG) peptidase activity of PSMA, the relative affinities of DCMC and DCIT for PSMA were determined using a previously published NAAG peptidase assay (17) . Briefly, NAAG peptidase activity was determined using membranes of Chinese hamster ovary cells stably transfected with rat GCPII, 4 Amol/L NAAG as a substrate, and a trace amount of [ 3 H]NAAG. Inhibitors at concentrations of 0.1, 0.3, 1, 3, 10, 30, 100, 300, and 1,000 nmol/L were tested. Product was separated using ion-exchange chromatography (AG-50W-X8 analytic grade cation-exchange resin). The amount of [ 3 H]glutamate as a product of NAAG hydrolysis was determined by scintillation spectrophotometry.
In vivo biodistribution. Statistical analysis. StatView 5.0 (SAS Institute, Inc., Cary, NC) was used for statistical analysis. A paired t test was used to assess for differences in tumor radiopharmaceutical uptake between different tissues. Ps < 0.01 were considered significant. DCIT are readily synthesized and show high affinity to PSMA. An important feature of any new radiopharmaceutical is the ability for it to be generated in radiolabeled form easily (i.e., introduction of the radiolabel in the last step of the synthesis, in high yield, and in high specific radioactivity). 
Results and Discussion

125
I was chosen for these studies because of its low cost, its ready availability, and its ability to be imaged in animal models of human cancer easily using a dedicated small animal device. Synthesis of the urea-based precursors to these compounds, which can provide access to a wide variety of structural analogs, is very straightforward, proceeding in only a few steps from the corresponding amino acids (13) .
The affinities of DCMC, DCIT, and their precursors were measured in a GCPII-based assay (17) . It is the NAAG peptidase (NAALADase) activity of GCPII that confers the PSMA-binding characteristics to these compounds because PSMA and NAALADase are the same enzyme (24, 25) . DCMC and DCIT are not substrates for PSMA but are believed to bind electrostatically to the active site (26) so that PSMA is essentially behaving as a receptor for these ligands. The K i values of DCMC and DCIT are 1.9 and 1.5 nmol/L, respectively, well within the range necessary for successful receptor-based radiopharmaceuticals (27) . (28, 29) . The kidney is therefore the target organ and provides an initial screen for agents likely to bind to PSMA-positive prostate cancer. Mouse prostate does not contain appreciable levels of PSMA (14, 30 (Fig. 1A) is selective, noted by decreased radioactivity within kidneys on the blocked images (Fig. 1B) . That finding was in support of our earlier work demonstrating specific binding in an ex vivo biodistribution assay (14) . Figure 2 (12) . Figure 3A shows that renal activity is essentially absent in the knockout mouse after administration of [
125 I]DCIT, indicating further that the high renal uptake noted in the ex vivo biodistribution assay (Table 1) (31 -33) . The only clinically approved prostate cancer -specific imaging agent, ProstaScint, involves a radioimmunodiagnostic method that made much use of LNCaP-derived xenografts during preclinical development to show binding specificity (32) . Other, potentially clinically superior, PSMA-based radioantibodies have also been evaluated initially in LNCaP-derived tumors (34) . We used LNCaP-derived xenografts as a model for PSMA-positive tumors and PC-3 (prostate cancer) and MCF-7 (breast cancer) xenografts as PSMA-negative controls. . Notably, the criteria for ProstaScint to progress to the clinic required a 3:1 tumor/muscle (background) ratio in s.c. LNCaP tumors, and a similar uptake ratio shown in the clinic provided a positive predictive value for the presence of prostate cancer at >90% (29) . Nevertheless, ProstaScint is the current clinical standard and any potential new prostate cancer imaging agent must prove superior or at least complementary to it.
Imaging studies employing PET and planar gamma scintigraphy corroborated highest PSMA-based binding of (Fig. 1B) . Despite the lower LNCaP tumor uptake of [
125 I]DCIT, clear images of the tumor could be delineated ( Fig. 2C and D) .
Implications for human prostate cancer diagnosis and therapy. As suggested at the outset, prostate cancer is the leading cancer in men and the second most common cause of cancer-related death. Furthermore, by the time of diagnosis, only half of the tumors are clinically localized and half of those represent extracapsular spread (35) . Sensitive, functional imaging techniques are needed to (a ) identify the extent of disease (metastases) in local lymph nodes before therapy, (b) identify the site of recurrence in patients with increasing serum prostatespecific antigen after surgery, and (c) study the surgical/ radiotherapy bed without the confounds of blood pooling and other prohibitive pharmacokinetic phenomena that are characteristic of currently available agents. We believe that our small-molecule agents will possess the necessary characteristics to meet those challenges.
We emphasize that these are low molecular weight imaging agents (f300 g/mol) because of the potentially salutary pharmacokinetics of such agents for tumor imaging. Bloodborne molecules, whether therapeutic or diagnostic agents, must reach the tumor vasculature, cross the vessel wall to the interstitium, and then migrate through the interstitium to the target sites, which may be intracellular (9) . There are microvascular barriers to the delivery of agents to tumors, which have a high interstitial fluid pressure due to collagen content and structure and high vascular permeability. The average uptake of agents to tumors actually decreases as the tumor increases in size (36) . We believe that our smallmolecule agents will gain access to their target sites more easily than antibody (i.e., ProstaScint) or polymeric agents (37) .
Our agents bind to the extracellular active site of PSMA. That may be another advantage over ProstaScint, which binds to an internal epitope of PSMA, suggesting that cells must be dead or dying for ProstaScint to gain access to the target (6, 7) . Arguably, the dead and dying cells will not represent the most aggressive elements of the tumor and would be less relevant targets for imaging. Prostate tumors tend to be small and vital, with little necrosis (38) . Because of the heterogeneous tumor vasculature, an antibodymediated agent may not gain access to all portions of the tumor, whereas a small molecule might. The large size of antibodies tends to increase their serum half-life so that there is slow diffusion from the tumor vasculature (39) . Such prolonged clearance kinetics and slow tumor uptake provide low radiolocalization indices and high background radioactivity. Those findings have been the basis of the development of minibodies and diabodies (i.e., strategies to preserve the targeting specificity inherent to antibodies while decreasing their molecular weight to improve pharmacokinetics for imaging and therapy).
In addition to the benefits discussed above for imaging prostate cancer, PSMA is present in the neovasculature of a variety of tumors, including non -small cell lung cancer, colorectal carcinoma, and glioblastoma, suggesting that our agents may enable imaging of a wide variety of tumors. That has further implications for therapeutic monitoring of antiangiogenesis or antivascular therapies. We may also be PMPA decreased uptake within renal cortex (site of proximal tubules, replete with PSMA), but neither of these PSMA-negative tumors could be imaged clearly with this agent.
